Publication details

Computer-assisted stabilization of fibroblast growth factor FGF-18

Investor logo
Investor logo
Authors

VILÍM Jan GHAZALOVÁ Tereza PETULOVÁ Eliška HORACKOVA Aneta STEPANKOVA Veronika CHALOUPKOVÁ Radka BEDNÁŘ David DAMBORSKÝ Jiří PROKOP Zbyněk

Year of publication 2023
Type Article in Periodical
Magazine / Source Computational and Structural Biotechnology Journal
MU Faculty or unit

Faculty of Science

Citation
Web https://www.sciencedirect.com/science/article/pii/S2001037023003665?via%3Dihub
Doi http://dx.doi.org/10.1016/j.csbj.2023.10.009
Keywords Computer-assisted stabilization; Fibroblast growth factor; Thermostability; Resistance to; Protease; Improved yield; FGF-18
Description The fibroblast growth factors (FGF) family holds significant potential for addressing chronic diseases. Specifically, recombinant FGF18 shows promise in treating osteoarthritis by stimulating cartilage formation. However, recent phase 2 clinical trial results of sprifermin (recombinant FGF18) indicate insufficient efficacy. Leveraging our expertise in rational protein engineering, we conducted a study to enhance the stability of FGF18. As a result, we obtained a stabilized variant called FGF18-E4, which exhibited improved stability with 16 degrees C higher melting temperature, resistance to trypsin and a 2.5-fold increase in production yields. Moreover, the FGF18-E4 maintained mitogenic activity after 1-week incubation at 37 degrees C and 1-day at 50 degrees C. Additionally, the inserted mutations did not affect its binding to the fibroblast growth factor receptors, making FGF18-E4 a promising candidate for advancing FGF-based osteoarthritis treatment.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info